Conference News More
The 14th International Conference on the Radiopharmaceutical Therapy (ICRT) will be held in Nanjing from August 21 to 24, 2019. This conference will offer to our Chinese and International Colleagues a unique opportunity to learn about the recent advances,
All participants are kindly requested to register individually through our on-line registration system. For participants who would like to present their abstracts at any scientific Session, registration and payment must be confirmed by May 31, 2019. The o
The International Conference on the Radiopharmaceutical Therapy (ICRT) is the first organized meeting in the field of radiopharmaceutical therapy and a prestigious international scientific event. We are pleased to inform you that the 14th ICRT will be hel
Feng Wang was born in Changshu, Jiangsu province, China, in 1972. He received his BS in 1991 from China Nanjing Medical University. He worked as a internal physician in Changshu people’s hospital from 1996 to 1998. He received his Master of Medicine in Nuclear Medicine from the Suzhou University, he worked as a nuclear medicine physician in Nanjing First Hospital after graduation. He received his MD in Nuclear Medicine in 2007 under the supervision of Professor Wu JinChang. After a five-year research program at a private company, he joined the Molecular Probe Program in the National Institute of Radiological Sciences' (NIRS) Molecular Imaging Center, in 1998 under the directorship of Dr. Kazutoshi Suzuki and was promoted to leader of the Radiochemistry Team in 2006. In the spring of 2012, he was promoted to leader of the Molecular Probe Program of the NIRS. He is also a visiting professor of the Graduate School of Pharmaceutical Sciences of Tohoku University. He specializes in the development of novel positron emission tomography (PET) probe that is useful for clinical research and imaging of biological function and production of high-quality PET probes for clinical research. He is also performing the development of new labeling techniques and reactions for PET probes.
Besides a few patents prof Kairemo has published more than 250 original articles in peer-reviewed journals. He received the Lifetime Achievement Award from the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH) and was President of the 7th International Conference on Radiopharmaceutical Therapy held in November 2012 in Levi in Finnish Lapland. In 2014, Dr Kairemo hosted ISORBE Symposium and Workshop “Cell Labelling and Cell Therapies” in Helsinki. He organized also the International Symposium on Radiopharmaceutical Therapy (WARMTH) in November 2018 in Helsinki.
Professor Li Yaming is the director of the Department of Nuclear Medicine of the First Affiliated Hospital of China Medical University. He is currently the chairman of the Tenth National Committee of the Chinese Medical Association Nuclear Medicine Branch, the vice chairman of the Nuclear Medicine Branch of the Chinese Nuclear Society, and the first session of the Chinese Medical Association Nuclear Medicine Physician Branch. Vice Chairman of the Committee, Editor-in-Chief of the Chinese Journal of Nuclear Medicine and Molecular Imaging, and the Standing Editors of the National Physician's Periodic Review and Editing Committee of the Chinese Medical Doctor Association.
Zhu Xiaohua, female, Director, Department of Nuclear Medicine, Department of Imaging Medicine, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Chief Physician, Professor, Doctor and Master Tutor, Doctor of Imaging Medicine and Nuclear Medicine. Visiting Scholar, Molecular Imaging Center, Department of Radiology, Medical College, Stanford University, USA. Short-term clinical training in the Department of Nuclear Medicine, Isa Right Bank Hospital, Munich University of Technology, Germany, and the Department of Nuclear Medicine, Philadelphia Children's Hospital, University of Pennsylvania. He has been engaged in clinical, teaching and scientific research of nuclear medicine for a long time. Research direction: Molecular imaging and oncology nuclear medicine. He presided over a number of National Natural Science funds, provincial, ministerial, school-level natural science funds and hospital-level clinical new technologies; participated in the national science and technology support project, joint fund major projects and a number of National Natural Science Foundation projects; chief editor, deputy editor and co-editor of a number of books and textbooks; published many articles in SCI;
Professor Li Sijin is the president of Shanxi Medical University, the director of Nuclear Medicine Department of the First Hospital of Shanxi Medical University, the chairman of the Nuclear Medicine Branch of the Chinese Medical Association, the vice-chairman of the Nuclear Medicine Branch of the Chinese Medical Association, and the vice-chairman of the Nuclear Medicine Branch of the Chinese Nuclear Society.
Guan Yihui, male, deputy chief physician, professor, deputy director of PET Center of Huashan Hospital Affiliated to Fudan University. He graduated from Shanghai Medical University in 1990. He is a doctor of medicine and doctoral supervisor. He is mainly responsible for the daily operation of clinical and Department of PET Center. He is good at the clinical application of PET/CT, neuronuclear medicine, quality control of nuclear medicine and computer image processing. Professor Guan participated in the PET and PET/CT diagnostic work since the establishment of the PET Center in Huashan Hospital. He presided over the completion of more than 50,000 PET and PET/CT examinations, and was responsible for the completion of external PET consultation and cadre health care work in our hospital. In recent years, he has published more than 30 papers on the application of PET and PET/CT in tumors, nervous system diseases and the quality control of PET instruments in domestic and foreign magazines with the first author and correspondent author. He has edited more than 20 books, and has undertaken six major projects of the Shanghai Science and Technology Commission, and participated in the national 10th Five-Year Key Issues and 973 projects.
Dr. Weibo Cai is an Associate Professor of Radiology and Medical Physics (with Tenure) at the University of Wisconsin - Madison. He received his Ph.D. degree in Chemistry from the University of California, San Diego in 2004, and did his postdoctoral research at the Molecular Imaging Program at Stanford University. In February 2008, Dr. Cai joined the University of Wisconsin - Madison as a Biomedical Engineering Cluster Hire, and his research there has focused on molecular imaging and nanotechnology.
Dr. Cai has authored ~150 peer-reviewed articles, 17 book chapters, and more than 160 conference abstracts. In addition, he has edited 2 books (1 more in the process) and given ~120 talks. Dr. Cai has received many prestigious awards, including the Society of Nuclear Medicine Young Professionals Committee Best Basic Science Award (2007), the European Association of Nuclear Medicine Springer Prize (2011 & 2013), European Association of Nuclear Medicine Eckert & Ziegler Abstract Award (2012), American Cancer Society Research Scholar (2013-2017), NIH R01, among many others. But what he is most proud of is that his trainees at UW-Madison have received >30 awards (e.g. 2012 Berson-Yalow Award from the Society of Nuclear Medicine and Molecular Imaging).
Dr. Cai has served on the editorial boards of many scientific journals, performed peer review for >110 journals, participated in many grant review panels, served on various committees of scientific societies (e.g. SNMMI), and chaired sessions at multiple international conferences. Prof. Cai is currently the Executive Editor of the American Journal of Nuclear Medicine and Molecular Imaging, which was launched in 2011 and is currently fully indexed in PubMed.
Professor, Chief physician, Director of nuclear medicine, Doctoral tutor
Research fields: Nuclear medicine diagnosis and treatment, Clinical application of new positron imaging agents, Clinical study of PET/CT dynamic imaging method.
1. Visiting Scholar, Department of Nuclear Medicine, Johns Hopkins Hospital, USA
2. Member of the positron photographic group of the Chinese Medical Association Nuclear Medicine Branch
3. Deputy Head of the Continuing Education Group of China Nuclear Medicine Beijing Branch
4. Member of the Molecular Imaging Professional Committee of the Chinese Society of Biophysics
5. Editorial Board of 《Chinese Journal of Nuclear Medicine and Molecular Imaging》, 《Chinese Journal of Medical Imaging》, etc.
Professor, Chief physician, Director of nuclear medicine, Doctoral tutor
Research fields: Basic and clinical application of tumor molecular nuclear medicine and multimodal molecular imaging.
1. Central Military Commission Health Committee consultation expert
2. Vice Chairman of the Chinese Medical Association Nuclear Medicine Branch
3. Chairman of the National Molecular Imaging and Nuclear Medicine Committee
4. Chairman of the National Military Medical Equipment Quality and Safety Control Committee
5. Member of the Standing Committee of the Nuclear Medicine Branch of the Chinese Medical Doctor Association
6. Chairman of the Shaanxi Provincial Nuclear Medicine and Molecular Imaging Branch
7. Vice Chairman of Shaanxi Nuclear Society
8. Deputy Director of the Imaging Diagnosis Branch of Shaanxi Anti-Cancer Association
Professor, associate dean
Research fields: Surgical and individualized comprehensive treatment of liver cancer, colorectal cancer liver metastasis and soft tissue tumor.
1. Member of the General Committee of the Chinese Medical Doctor Association
2. Vice Chairman of the Soft Tissue Sarcoma Branch of China Anti-Cancer Association
3. Wu Jieping Medical Foundation, Deputy Director, Hepatology Intervention Group, Department of Hepatology, Medical College
4. Member of the Oncology Committee of the Chinese Medical Association Beijing Branch
Chief physician, Master Instructor, Deputy director of hepatobiliary surgery
Research fields: Surgical treatment of liver metastases, neuroendocrine tumors and hepatocellular carcinoma of colorectal cancer.
1. Secretary General of the Chinese Society for the Promotion of Neuroendocrine Cancer
2. Deputy Chairman of the Youth Committee of the Beijing Medical Association Oncology Branch
3. Director General of the Youth Committee of the Liver Cancer Branch of the China Council for the Promotion of Traditional Chinese Medicine
Medical University of Innsbruck, Austria
Director of nuclear medicine, Professor, Doctoral tutor
Research fields: Radionuclide therapy for hyperthyroidism, hyperthyroidism, and tumor bone metastasis.
1. Member of the Chinese Medical Association Nuclear Medicine Branch
2. Chairman of the Lymphoma PET/CT Committee
3. Deputy Director of the Imaging Professional Committee of the Chinese Women's Physician Association
4. Chairman of the Clinical Committee of the Shanghai Nuclear Society
5. Editorial Board of China Nuclear Medicine Journal
6. Editor-in-Chief of Cancer Imaging
Docrates Cancer Center, Finland
Chief physician, Doctoral tutor
Research fields: PET/CT imaging for early diagnosis of tumor, 131I treatment of refractory thyroid disease
1. Member of the 10th and 11th Sessions of the Chinese Medical Association Nuclear Medicine Branch
2. The 3rd member of the Nuclear Medicine Branch of the Chinese Medical Doctor Association
3. Vice Chairman of the Ninth Youth Committee of the Chinese Medical Association Nuclear Medicine Branch
4. Deputy Chairman of the Clinical Nuclear Medicine Committee of Shanghai Nuclear Society
5. Member and Secretary of the Shanghai Medical Association Nuclear Medicine Professional Committee
6. Editorial Board of 《International Journal of Radiation Medicine and Nuclear Medicine》 and 《Chinese Journal of Nuclear Medicine and Molecular Imaging》
Hong Zhang, professor, doctoral tutor, special professor of Zhejiang University. He was winner of the National Science Fund for Distinguished Young Scholars, distinguished Professor of the National “Millions of Programs”, chief Scientist of the “National Key Research and Development Program” (Stem Cell Special Project), and Honorary Professor of the Hong Kong Polytechnic University.
Currently, he is assistant to the Dean of Zhejiang University School of Medicine, Director of the Medical PET Center of Zhejiang University, Director of the Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University, and Director of the Department of Nuclear Medicine of the Second Affiliated Hospital of Zhejiang University School of Medicine. He is a member of the Standing Committee of the Party Committee and Vice President of Shanxi Medical University.
He studied at the National Ministry of Medicine of Gunma University, the National Institute of Radiological Medicine in Japan, and the St. Barth Hospital of the University of London.
Department of Nuclear Medicine,Autonomous University of Barcelona, Irene Virgolini, Medical University of Innsbruck, Austria
Changjing Zuo, male, professor, doctoral tutor, director of nuclear medicine department of Changhai Hospital. He was selected into the "Dawn Plan" of Shanghai Municipal Education Commission and the outstanding talent pool of the "5511" project. He has served as editorial board of 2 core periodicals. And more than 100 academic papers have been published, including 4 SCI papers; 2 editor-in-chief works, and 5 books.
He is engaged in imaging medicine and nuclear medicine, and is good at CT diagnosis and CT-guided interventional therapy. He is engaged in imaging medicine and nuclear medicine, and is good at CT diagnosis and CT-guided interventional therapy. Conducted alcohol-assisted ablation of adrenal functional tumors under CT guidance, celiac plexus block for intractable refractory upper abdominal cancer pain, myasthenia gravis, microwave radiation and alcohol ablation, and radiofrequency (RF) of liver cancer More than 10 CT interventional techniques for ablation and electrochemotherapy (EChT), malignant tumor I125 radiation seed implantation, and malignant tumor interstitial implantation; comprehensive imaging of spiral CT angiography and pancreatic lesions There are certain rumors in diagnosis and other aspects.
Hans Jürgen Wester
Pharmaceutical Radiochemistry Technical University Munch, Germany
Maode Lai, male, professor, current president of China Pharmaceutical University, academician of German Academy of Sciences, chairman of Pathology Branch of Chinese Medical Association; vice president of pathologist branch of Chinese Medical Association; vice chairman of teaching research association of national higher education; education Deputy Director of the Basic Medical Teaching Steering Committee; Vice President of Zhejiang Medical Association; Editor-in-Chief of Zhejiang University Journal (Medical Edition); Associate Editor of Chinese Journal of Pathology; Associate Editor of Clinical and Experimental Pathology; Associate Editor of JZJU; ClinicaChimica Acta Journal Editorial Board; Adjunct Professor at Alberta University, Canada; Designed as the Chief Scientist and Received the National Eleventh Five-Year National Science and Technology Support Program “Early Identification and Intervention Techniques for Metabolic Syndrome”. He has presided over more than 20 major projects such as the National Natural Science Foundation of China and the Science and Technology Department of Zhejiang Province. He has won 6 provincial and ministerial scientific research awards, including 1 first prize of Zhejiang Science and Technology Progress Award. 3 second prizes for national education achievements. Person in charge of the national quality course "Pathology"
Jie Chen, female, chief physician, deputy director of Department of Gastroenterology, First Affiliated Hospital of Sun Yat-sen University. Currently, she is a member of the European Neuroendocrine Tumor Society (ENETS), a leader of the Chinese Study Group for Neuroendocrine Tumor (CSNET), a member of the Standing Committee of the Chinese Anti-Cancer Association Pancreatic Cancer Professional Committee, deputy head of the oncology group of the Digestive Disease Branch of the Guangdong Medical Association, deputy director of the Digestive Disease Branch of the Guangdong Medical Association, standing committee member of the gastric cancer professional committee of the Guangzhou Anti-cancer Association, editorial board member of the Chinese Journal of Digestive Communications, editorial board member of the Digestive disease Channel in Medical Reference, editorial board member of The Lancet Gastroenterology & Hepatology China Edition. She is good at diagnosis and treatment of gastrointestinal pancreatic neuroendocrine tumors. As the project leader, he presided over a number of scientific research funds including the National Natural Science Foundation. He has published more than 70 academic papers, including more than 40 papers published in well-known international academic journals such as Journal of Clinical Oncology, Gut, Carcinogenesis, J Proteome Res, etc. Obtaining exchange opportunities in many large international academic conferences; Participating in the compilation of 6 monographs.
Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Japan
Hongcheng Shi, male, doctor, professor, chief physician, doctoral tutor, director of nuclear medicine department of Zhongshan Hospital affiliated to Fudan University, director of nuclear medicine research institute of Fudan University, deputy director of Shanghai Institute of Imaging Medicine. His main area is nuclear medicine, good at precise diagnosis and treatment which is based on nuclear medicine imaging. Treatment programs include radionuclide therapy for the treatment of thyroid diseases, and radionuclide analgesic treatment for tumor bone metastasis.
J. Harvey Turner
University of Western Australia, Australia
Hui Wang, chief Physician, Ph.D.Supervisor, is the director of the Nuclear medicine Department of Xinhua Hospital affiliated to Shanghai Jiao Tong University. Currently, he holds the deputy director of the the vice chairman of Chinese Society of Nuclear Medicine, the Standing Committee of the Nuclear Medicine Branch of the Chinese Medical Doctor Association, the former chairman of the Shanghai Nuclear Medicine Branch, and the executive editor of Chinese Journal of Nuclear Medicine and Molecular Imaging. Currently, he is mainly engaged in the PET/CT diagnosis of childhood cancer, and the basic and clinical research of 131I in the treatment of hyperthyroidism and oncology. At present, he has undertaken a number of national and provincial-level projects. In recent years, he has published more than 30 SCI articles.
Fang Li, male, chief physician, doctoral supervisor, director of nuclear medicine department of Peking Union Medical College Hospital. Academic positions include the chairman of the Nuclear Medicine Special Committee of China Association of Medical Equipment, the vice chairman of Chinese Society of Nuclear Medicine, the vice chairman of Molecular Imaging Branch of Biophysical Society of China, the deputy chairman of Chinese Society Of Research Hospitals Parathyroid and Bone Metabolic Disease Professional Committee, Deputy Editor of Chinese Journal of Nuclear Medicine, etc.
Min Yang received her B.S. degree in Chemistry from Jilin University in1993 and then started to work in Jiangsu Institute of Nuclear Medicine (JSINM). At 2001, she got her M.S. degree in Nuclear Medicine from China Medical University. China Pharmaceutical University awarded her a Ph.D. degree in Pharmacology in 2005. From 2010 to 2011, Dr. Yang was a Visiting Scholar in National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute of Nuclear Medicine (NIH), Bethesda, USA. From 2013 to 2014, she held Visiting Professor at the Department of Radiology and Bio-X Program, School of Medicine, Stanford University. At present, she was appointed to be the Chief of Molecular Imaging Center at JSINM.
Professor Yang’s research is involved in accurate diagnosis and image-guided personalized treatment for cancers, nervous system, and other diseases. She has developed: 1)Production of 18F , 68Ga, 64Cu, 89Zr, 177lu, 99mTc and 131/125I radiopharmaceuticals for PET and SPECT; 2) hybrid contrast media for PET/MRI/PAI/CT and 3) technologies for theranostic approaches of cancers. She has authored more than 150 peer-reviewed publications. She also holds 33 patents and some of the patents were licensed in clinic translation. She serves on some editorial boards, such as American Journal of Nuclear Medicine and Molecular Imaging, Chinese Journal of Nuclear Medicine and Molecular Imaging, Isotope, and so on. She was honored a State Council Expert for Special Allowance at 2010. She has won more than 20 prizes such as the first prize for scientific and technological progress of the
Ministry of Education, the second prize for scientific and technological progress in
Jiangsu Province, etc.
Mingyuan Gao, Ph.D
State Key lab for Radiation Medicine and Protection
Chair Professor, Deputy Head
School of Radiation Medicine and Protection, Soochow University
199 Ren Ai Road, Industrial Park, Suzhou 215123, China
Tel: +86-10-8261-3214, Email: email@example.com
Dr. Gao is a full Professor in the Institute of Chemistry, Chinese Academy of Sciences (CAS) and a Chair Professor at School of radiation medicine and Protection, Soochow University. He received his BSc (1989) and PhD (1995) in Polymer Chemistry and Physics at Jilin University. He was a postdoc and an AvH fellow between 1996 and 1998 at Max-Planck-Institute of Colloids and Interface, and a group leader between 1998 and 2001 at University of Munich, Germany. He took the current position upon a ‘Hundred-talent Program’ of CAS in 2001. He received an award for Distinguished Young Scholars from NSFC in 2002. In 2013, he was appointed as a Chair Professor and Director of the Centre for Molecular Imaging and Nuclear Medicine, School for Radiological and Interdisciplinary Sciences, Soochow University. With a cumulative impact factor (IF) point of 1000+, he has published 160+ peer-reviewed articles and the total citation number is 10000+. Among them, 40+ articles are published in journals with IF higher than 10. Dr. Gao holds 16 patents including US patents.